Treatment options for patients with large cell neuroendocrine carcinoma of the lung

Gen Thorac Cardiovasc Surg. 2014 Jun;62(6):351-6. doi: 10.1007/s11748-014-0379-9. Epub 2014 Apr 10.

Abstract

Large cell neuroendocrine carcinoma (LCNEC) of the lung is categorized as a variant of large cell carcinomas, and LCNEC tumors display biological behaviors resembling those of small cell lung carcinomas and features of high-grade neuroendocrine tumors. Because patients with LCNEC have a poor prognosis, surgery alone is not sufficient. Multimodality therapies, including adjuvant chemotherapy, appear promising for improved prognosis in patients with LCNEC. In this review article, we discuss treatment options for patients with LCNEC of the lung.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Large Cell / drug therapy
  • Carcinoma, Large Cell / pathology
  • Carcinoma, Large Cell / surgery*
  • Carcinoma, Neuroendocrine / drug therapy
  • Carcinoma, Neuroendocrine / pathology
  • Carcinoma, Neuroendocrine / surgery*
  • Combined Modality Therapy
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Prognosis

Substances

  • Antineoplastic Agents